Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2018 - IJCMAS--ICV 2018: 95.39 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020]For more details click here

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2020)
[Effective from January 1, 2020]
For more details click here

ICV 2018: 95.39
Index Copernicus ICI Journals Master List 2018 - IJCMAS--ICV 2018: 95.39
For more details click here

See Guidelines to Authors
Current Issues

Original Research Articles

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com / submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38

Int.J.Curr.Microbiol.App.Sci.2020.9(6): 2217-2227
DOI: https://doi.org/10.20546/ijcmas.2020.906.271


Pathogenesis of SARS-CoV-2 and Important Insights on its Potent Inhibitors Remdesivir and Chloroquine - A Review
Meeti Punetha1, Bosco Jose2, Jaya Bharatiand Mihir Sarkar2*
1ICAR-Central Institute for Research on Buffaloes, Hisar, Haryana-125001, India
2Physiology & Climatology Division, ICAR-Indian Veterinary Research Institute,Izatnagar, Bareilly, Uttar Pradesh-243122, India
3ICAR-NationalResearch Centre on Pig, Animal Physiology Guwahati, Assam, India
*Corresponding author
Abstract:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is enveloped, single-stranded, positive- sense RNA virus which is responsible for coronavirus disease 2019 (COVID-19) characterized by pulmonary infection in humans. Effective prophylactic and therapeutic management for COVID-19 are urgently required to control this pandemic. Angiotensin-converting enzyme 2 (ACE2) is the receptor for SARS-CoV-2 in host cell. Spike protein of virus bindswith the peptidase domain of ACE2 receptor. After binding with the receptor the next step of virus is to gain entry to the host cell cytosol which is accomplished by the proteolyti cleavage of S protein in acidic pH. The proteolytic cleavage is followed by fusion of SARS-CoV-2 and its host cell membrane leading to release of the viral genomeinto the cytoplasm. The anti-malarialdrug chloroquine and its analog hydroxy-chloroquine are known to restrict viral replication by increasing endosomal pH which inhibits viral-cell fusion. After uncoating, viral RNA genome is translated to form structural viral protein with the help of RNA-dependent RNA polymerase (RdRp), which is the target for adenosine analogue remdesivir. The combination therapy including Remdesivir and chloroquine are exceptionally successful in the control of 2019-nCoV disease in vitro. Fundamental preliminaries of Remdesivir and chloroquine repurposing in the treatment of COVID-19 have been empowering, prompting a few new trials. In this review, pathogenesis of the SARS-CoV-2 and the potential mechanism of two potent inhibitors remdesivir and chloroquine as effective therapeutic agents against COVID-19 are described.


Keywords: single-stranded, positive- sense RNA virus
Download this article as Download

How to cite this article:

Meeti Punetha, Bosco Jose, Jaya Bharati and Mihir Sarkar. 2020. Pathogenesis of SARS-CoV-2 and Important Insights on its Potent Inhibitors Remdesivir and Chloroquine - A Review.Int.J.Curr.Microbiol.App.Sci. 9(6): 2217-2227. doi: https://doi.org/10.20546/ijcmas.2020.906.271